EICHORCondition: Healthy Participants Study · Sponsor: Shanghai Argo Biopharmaceutical Co., Ltd.
Phase 1, Single Ascending Dose Study of Subcutaneous BW-50218 in Healthy Participants
This description comes directly from the study's public registry record.
Zhi Hua · +86 185 1618 7545 · zhi.hua@argobiopharma.com
Always discuss trial participation with your own doctor first.
| CMAX Clinical Research Pty Ltd | Adelaide, South Australia, Australia | Recruiting |
| Linear Early Fhase Limited | Nedlands, Western Australia, Australia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07401472